Cargando…
FRI344 Is It Possible To Have Two Endocrinopathies From Checkpoint Inhibitor Therapy At The Same Time?
Disclosure: A.N. Davis: None. G. Elshimy: None. Introduction: Checkpoint inhibitor (CPI) therapy with ipilimumab and nivolumab has become commonly used in patients with metastatic melanoma. Endocrinopathies, including hypophysitis and thyroiditis, have been reported as adverse effects. These endocri...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Oxford University Press
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10554346/ http://dx.doi.org/10.1210/jendso/bvad114.1278 |